Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q4 FY24 results · Jan–Mar 2024
Astec LifeSciences reported revenue from operations of ₹153.75 crore (up 21.1% from Q4 FY23) and net loss of ₹0.96 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 153.75 | 126.97 | +21.1% | 50.79 | +202.7% |
| Other income | 2.05 | 2.57 | −20.5% | 0.91 | +125.1% |
| Total income | 155.80 | 129.55 | +20.3% | 51.70 | +201.3% |
| Profit before tax | (0.93) | (6.18) | Loss narrowed | (32.22) | Loss narrowed |
| Net profit for the period | (0.96) | (4.97) | Loss narrowed | (24.33) | Loss narrowed |
| Attributable to shareholders of the company | (0.97) | (4.98) | Loss narrowed | (24.33) | Loss narrowed |
| EPS, basic (₹) | 0.50 | (2.54) | Turned profit | (12.41) | Turned profit |
| Net margin (%) | -0.6 | -3.9 | -47.9 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 153.75 | 126.97 | +21.1% | 50.79 | +202.7% |
| Other income | 2.03 | 2.57 | −20.8% | 0.90 | +125.8% |
| Total income | 155.78 | 129.54 | +20.3% | 51.69 | +201.3% |
| Profit before tax | (0.96) | (6.21) | Loss narrowed | (32.25) | Loss narrowed |
| Net profit for the period | (0.99) | (5.00) | Loss narrowed | (24.35) | Loss narrowed |
| EPS, basic (₹) | 0.50 | (2.55) | Turned profit | (12.42) | Turned profit |
| Net margin (%) | -0.6 | -3.9 | -47.9 |
Consolidated
- Filed with BSE
- 08 May 2024, 17:28 IST
- Board meeting
- 02 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 May 2024, 17:28 IST
- Board meeting
- 02 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE